Search Results 621-630 of 19233 for hemoglobin

  1. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 x 10^9/L, platelet count ≥ 75 x 10^9/L, hemoglobin ≥ 10.0 g/dL). Adequate ...

  2. A Study of Bezisterim (NE3107) in Adults with Long COVID - Mayo Clinic

    Hemoglobin ≤ 10 g/dL if female, ≤11.5 g/dL if male; International normalized ratio (INR) > 1.5 if not on anticoagulant medication; if the participant is on ...

  3. Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer - Mayo Clinic

    Hemoglobin > 9.0 g/dL; Total serum bilirubin ≤ 2 mg/dL; Aspartate transaminase (AST) ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN in patients with liver ...

  4. A Study of Pembrolizumab (MK-3475) Versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer - Mayo Clinic

    Hemoglobin* ≥ 9 g/dL or ≥ 5.6 mmol/L. Renal. Creatinine ≤ 1.5 × ULN; OR; Measured or calculated** creatinine clearance (GFR can also be used instead of ...

  5. Study of Magrolimab Combination Therapy to Treat Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    hemoglobin inclusion criteria. - History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months. - Prior treatment with ...

  6. Home Care Treatment With Oral Chemotherapy For Recurrent Or Metastatic Oral Cavity Cancer - Mayo Clinic

    Hemoglobin ≥9.0 g/dL. Absolute neutrophil count (ANC) ≥1500/mm3. Platelet count ≥100,000/mm3. Total bilirubin ≤1.5 x ULN. Alanine aminotransferase (ALT) and ...

  7. A Study to Evaluate Injectafer® as Treatment for Heart Failure with Iron Deficiency - Mayo Clinic

    Hemoglobin > 9.0 g/dL and < 13.5 g/dL (females) or < 15.0 g/dL (males) within 28 days of randomization. Serum ferritin < 100 ng/mL or 100 to 300 ng/mL with ...

  8. A Study of 9-ING-41 in Patients with Advanced Cancers - Mayo Clinic

    hemoglobin ≥ 8.5 g/dL, platelets ≥ 50,000/mL 2. Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and ...

  9. Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection - Mayo Clinic

    Uncontrolled diabetes, defined as hemoglobin A1c > 7.4%. BMI > 45; Any acute illness within 14 days of Day 1 that could confound the evaluation of safety ...

  10. Belimumab With Rituximab for Primary Membranous Nephropathy (REBOOT) - Mayo Clinic

    Moderately severe anemia (hemoglobin \< 9 g/dL) 17. History of primary immunodeficiency 18. Serum IgA \< 10 mg/dL 19. Alanine aminotransferase (ALT) or ...